CLINICAL RESEARCH · DATA SCIENCE · RESPONSIBLE AI
Veralux connects responsible AI assistance with clinical research, medical, biostatistical, data and governance expertise—so complex work can move through one accountable evidence pathway.
Question → Data → Review → Evidence → Action
01 — THE PROBLEM
Fragmented Expertise
Clinical, statistical, data, compliance, and commercial decisions often sit across separate teams, creating repeated handoffs, higher coordination costs, and information loss.
Slow Evidence Generation
Study design, outreach, data collection, quality control, and analysis are frequently disconnected, delaying the path from a clinical question to a decision.
Complex Execution Pathways
Multi-institutional, multi-regional, and cross-border projects must navigate data governance, operational capacity, and compliance at the same time, making sustained execution difficult.
02 — THE SOLUTION
Problem Definition
Study Design
Targeted Outreach
Quality Control
Data Analysis
Decision Support
Veralux combines AI-assisted tools with expert judgment across problem definition, study design, targeted outreach, quality control, data analysis, and decision support—creating an efficient, reviewable, and human-governed workflow for clinical research and healthcare innovation.
03 — OUR PRODUCTS
End-to-end research and decision support from clinical questions to actionable evidence.
Study design · Statistical analysis · Quality control · Results interpretation · Bilingual reporting
AI Health Consulting combines study design, targeted outreach, statistical analysis, quality control, results interpretation, and bilingual reporting. AI supports the workflow, while experts retain responsibility for research judgment and final sign-off.
A site-controlled bridge connecting clinical data, human verification, anomaly detection, and EDC collaboration.
Read-only, site-controlled access · De-identification, privacy filtering, and minimum-necessary fields · AI-assisted structuring and field mapping · Rapid CRC verification · Missingness, range, cross-table, and trend checks · CRA collaboration and validated system interfaces
Within a read-only, site-controlled environment and a minimum-necessary-data model, the platform de-identifies, structures, and maps data from systems such as HIS, EMR, LIS, and PACS. It supports rapid CRC verification, AI-assisted anomaly detection, CRA collaboration, and validated transfer to EDC or related systems. Directly identifiable source data remain within the institution, with human review and final confirmation retained.
Product concept in development. Deployment is subject to institutional data governance, security review, interface validation, and project authorization.
From data preparation to statistical decision-making, enabling clinical research to be more efficient, rigorous, and secure.
EDC data intake and preparation · Data quality checks · Descriptive analytics · Sample size calculation · Clinical trial design · Enterprise knowledge retrieval
A one-stop intelligent statistical workspace for CRO biostatistics teams, covering EDC data intake and preparation, data quality checks, descriptive analytics, sample size calculation, clinical trial design, and enterprise knowledge retrieval. The platform supports on-premises private deployment, helping ensure that clinical data and core institutional knowledge remain within the enterprise security boundary. With a reproducible statistical engine and a controlled AI knowledge base, it helps teams improve analytical efficiency, strengthen data quality, and preserve professional expertise.
AI-assisted tender research and evidence organization for construction legal workflows.
Unified tender search · Notice classification · Structured field extraction · Project timelines · Source traceability · Review-ready exports
A structured workspace for searching public procurement and tender records, extracting key project and company information, connecting related announcements into project timelines, preserving source traceability, and preparing review-ready work products for legal professionals. Human review remains central to verification and interpretation.
AI-assisted prospecting and market development for B2B teams.
Terriva helps businesses turn market expansion goals into a more structured prospecting workflow. Teams can define their company, offering, target markets, and ideal customer profile, then use Terriva to identify relevant companies across selected industries and regions, understand why each prospect may be worth pursuing, and determine who to approach. It can also prepare account-specific outreach angles and email drafts, giving sales teams more time to evaluate opportunities and build relationships.
Automated launch-readiness red teaming for websites.
WebRedTeam is designed to help teams catch launch issues before customers encounter them. For websites the user owns or is authorized to review, it performs non-invasive checks across visual quality, conversion paths, mobile readiness, accessibility, baseline security hygiene, SEO, performance, code efficiency, broken links, and browser or network errors. It also captures desktop and mobile evidence and organizes the findings into a structured launch-readiness report. WebRedTeam is not a substitute for professional penetration testing; its role is to help teams identify, document, fix, and re-check issues before release.
04 — OUR ADVANTAGES
An Approximately 4–8 Week Core Workflow
For projects with a defined scope and appropriate approval, sampling, outreach, and data conditions, the core workflow from problem definition to bilingual delivery can be structured within approximately 4–8 weeks. Actual timelines depend on scope, approvals, sample targets, outreach channels, and data availability.
Human-Governed AI
AI assists outreach, screening, quality control, analysis, and report drafting. Medical judgment, methodological choices, interpretation, and final sign-off remain with qualified professionals.
Group-Backed Clinical and Operational Capabilities
Powered by the clinical and operational capabilities of PUSH-ZGC Pharmaceutical & Medical Device Group, projects can draw on clinical operations, medical writing, biostatistics, data management, regulatory affairs, quality management, and nationwide delivery resources.
Backed by Third-Round Financing
The group has completed its third round of financing, providing continued support for future product development, technical implementation, and project execution.
Selected Clinical and Industry Network
Veralux is the North American subsidiary of PUSH-ZGC Pharmaceutical & Medical Device Group, building on the Group's project experience and collaborative network across pharmaceuticals and medical devices. The Group has worked with the companies and healthcare institutions listed below on various projects. The nature and scope of each engagement have varied, and inclusion here does not imply that every organization has a direct, ongoing, or exclusive relationship with Veralux.
Pierre Fabre · Siemens · Johnson & Johnson · Thermo Fisher Scientific · Medtronic · Bayer · BGI · Tecan
Chinese PLA General Hospital · Peking Union Medical College Hospital · Fuwai Hospital, Chinese Academy of Medical Sciences · Beijing Tiantan Hospital, Capital Medical University · Ruijin Hospital, Shanghai Jiao Tong University School of Medicine · Fudan University Shanghai Cancer Center · West China Hospital, Sichuan University · The First Affiliated Hospital, Sun Yat-sen University
05 — THE TEAM
Our interdisciplinary team brings together backgrounds in public health, biostatistics, management, law, and clinical research. Members have educational experience at Johns Hopkins University, the University of North Carolina, and New York University, along with professional or project experience involving Pfizer, IQVIA, and Baker McKenzie FenXun. The team combines capabilities in study design, data analysis, compliance governance, and AI-assisted project execution.
GROUP EXPERT SUPPORT
The group’s clinical development organization includes nearly 100 professionals across clinical operations, medical affairs, biostatistics, data management, regulatory affairs, and quality management. More than 75% have over two years of CRO experience, and over 90% of the technical team hold medical-device and/or drug GCP credentials.
Jiang Yuanchao | Clinical Operations & IVD
20+ years of experience across pharmaceuticals and medical devices, including senior management experience at Sinopharm. He has led the development of the group’s clinical operations and IVD capabilities, with experience spanning innovative-drug and Class III IVD clinical trials and NMPA inspections.
Yu Na | Medical & Regulatory Affairs
Brings 10+ years of clinical practice and 10+ years of CRO experience, including six years as an attending thoracic surgeon, with extensive experience in oncology drug trials and clinical study design for advanced medical devices.
Zhang Chuanqing | Medical Device Clinical Operations
Holds a master’s degree in Clinical Medicine and brings 12 years of clinical-trial experience, including nine years in project and team management, across proton therapy, surgical robotics, cardiovascular, oncology, and aesthetic-device programs.
Zhang Yang | IVD Clinical Operations
Holds a master’s degree in Biomedical Engineering from Peking Union Medical College and brings 10+ years of clinical-operations experience, having led dozens of Class II and Class III IVD clinical trials across infectious disease, oncology, and other areas.
Gong Tingxian | Regulatory Affairs
Brings 20+ years of pharmaceutical and medical-device regulatory and legal experience, including extensive engagement with NMPA CDE/CMDE processes and familiarity with NMPA, FDA, and EMA regulatory frameworks.
Zhang Lu | Quality Management
Brings 10+ years of pharmaceutical and medical-device quality-management experience spanning QC, QA, GMP, ISO 13485, clinical quality systems, clinical-trial auditing, and regulatory inspections.
A member of our team supported the statistical analysis and manuscript refinement for a phase 1 study of intracranial T-cell therapy in refractory brain metastases and glioblastomas, and is acknowledged in the paper. The related article was published online in Cell Reports Medicine on August 5, 2026.
Educational and professional backgrounds are provided solely to describe team capabilities. No institutional endorsement, authorization, or sponsorship is implied.
06 — GET IN TOUCH
Ready to turn clinical questions into faster, credible, and actionable evidence? Connect with Veralux to discuss foundation support, clinical research, data collaboration, hospital and industry collaboration, and cross-border execution.
hongchen@veralux.health
+1 (917) 943-7106
33 S Wood Ave, Iselin, NJ 08830, United States
Please do not submit patient, health, clinical-trial or other sensitive personal data.